Eisai Co., Ltd.

MUN:EII0 Stock Report

Market Cap: €14.5b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Eisai Valuation

Is EII0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of EII0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: EII0 (€54.17) is trading below our estimate of fair value (€63.1)

Significantly Below Future Cash Flow Value: EII0 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EII0?

Key metric: As EII0 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EII0. This is calculated by dividing EII0's market cap by their current earnings.
What is EII0's PE Ratio?
PE Ratio78.6x
EarningsJP¥26.71b
Market CapJP¥2.10t

Price to Earnings Ratio vs Peers

How does EII0's PE Ratio compare to its peers?

The above table shows the PE ratio for EII0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47x
MRK Merck KGaA
18.9x7.41%€54.0b
DMP Dermapharm Holding
16.7x11.48%€1.9b
PSG PharmaSGP Holding
17.5xn/a€345.4m
SRT3 Sartorius
135.1x23.43%€15.6b
EII0 Eisai
78.6x25.11%€2.1t

Price-To-Earnings vs Peers: EII0 is expensive based on its Price-To-Earnings Ratio (78.6x) compared to the peer average (18.5x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does EII0's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
EII0 78.6xIndustry Avg. 25.0xNo. of Companies9PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EII0 is expensive based on its Price-To-Earnings Ratio (78.6x) compared to the European Pharmaceuticals industry average (21.4x).

Price to Earnings Ratio vs Fair Ratio

What is EII0's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EII0 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio78.6x
Fair PE Ratio20.9x

Price-To-Earnings vs Fair Ratio: EII0 is expensive based on its Price-To-Earnings Ratio (78.6x) compared to the estimated Fair Price-To-Earnings Ratio (20.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

€65.16
Fair Value
16.9% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/02 15:51
End of Day Share Price 2023/02/06 00:00
Earnings2022/12/31
Annual Earnings2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eisai Co., Ltd. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Miki SogiBernstein
Koichi MameganoBofA Global Research